PriceTargets.com logo

NSRX - NSRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 642.27%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.43 As of 03/26/2026 12:06 PM ET
▼ -0.335 (-12.14%)

This chart shows the closing price for NSRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NSRX Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NSRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NSRX

Analyst Price Target is $18.00
▲ +642.27% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for NSRX in the last 3 months. The average price target is $18.00, with a high forecast of $18.00 and a low forecast of $18.00. The average price target represents a 642.27% upside from the last price of $2.43.

This chart shows the closing price for NSRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in NSRX.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/26/2026Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$19.00 ➝ $18.00
(Data available from 3/26/2021 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2026
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2026
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/26/2026

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

NSRX

Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.
Read More

Today's Range

Now: $2.43
Low: $2.53
High: $2.67

50 Day Range

MA: $5.10
Low: $2.48
High: $7.10

52 Week Range

Now: $2.43
Low: $2.29
High: $9.99

Volume

16,877 shs

Average Volume

174,200 shs

Market Capitalization

$28.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NSRX?

The following Wall Street analysts have issued stock ratings on NSRX in the last twelve months: Citizens Jmp.
View the latest analyst ratings for NSRX.

What is the current price target for NSRX?

0 Wall Street analysts have set twelve-month price targets for NSRX in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 581.8%. Citizens Jmp has the highest price target set, predicting NSRX will reach $18.00 in the next twelve months. Citizens Jmp has the lowest price target set, forecasting a price of $18.00 for NSRX in the next year.
View the latest price targets for NSRX.

What is the current consensus analyst rating for NSRX?

NSRX currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NSRX will outperform the market and that investors should add to their positions of NSRX.
View the latest ratings for NSRX.

How do I contact NSRX's investor relations team?

NSRX's physical mailing address is YIGAL ALON 65, TEL AVIV - YAFO, L3 6744317, IL. The company's listed phone number is 972-3573-6632 and its investor relations email address is [email protected]. The official website for NSRX is www.nasus-pharma.com. Learn More about contacing NSRX investor relations.